INMD
NASDAQInMode Ltd.
Price$13.56+0.10 (+0.74%)
2026-03-052026-06-08
News · 26 weeks31+67%
2025-12-142026-06-07
Mix1990d
- Insider9(47%)
- Other3(16%)
- SEC Filings3(16%)
- Earnings2(11%)
- Leadership2(11%)
Latest news
25 items- PRAfter Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue regeneration — evolves, the next 18 months matter. NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary — For more than fifty years, breast reconstruction has mostly meant one thing: replacement. A silicone shell, filled with gel, designed to restore shape and volume, none of them designed to regenerate the breast's own living tissue. That gap has consequences. Roughly two-thirds of the more than 100,000 women in the United States who undergo a mastectomy ea
- INSIDERNew insider Moshe Itzkovich claimed ownership of 7,503 units of Ordinary Shares (SEC Form 3)3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERNew insider Nass Shlomo claimed no ownership of stock in the company (SEC Form 3)3 - InMode Ltd. (0001742692) (Issuer)
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial OfficerYOKNEAM, Israel, May 20, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately. Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accoun
- PRInMode to Present at Upcoming Investor Conferences and EventsYOKNEAM, Israel, May 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events: Barclays Virtual West Coast Bus TripPresenters: Yair Malca, Outgoing Chief Financial Officer and Moshik Itzkovich, Senior VP of FinanceFormat: Virtual investor bus tourWhen: Wednesday, May 20Jefferies Global Healthcare ConferencePresenters: Yair Malca, Outgoing Chief Financial Officer and Moshik Itzkovich, Senior VP of FinanceFormat: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst and one-on-one meetingsWhen: Wednesday, June 3, fireside chat at 12:45 p
- PRInMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year IncreaseYOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter of 2026. First Quarter 2026 Highlights:● Quarterly GAAP revenues of $82.0 million, compared to $77.9 million in the first quarter of 2025.● Quarterly revenues from consumables and service of $21.4 million, an increase of 6% compared to the first quarter of 2025.● GAAP operating income of $10.1 million, *non-GAAP operating income of $14.0 million.● Total cash po
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375MConference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
- PRInMode to Present at the 25th Annual Needham Virtual Healthcare ConferenceYOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 11:00 am Eastern Time on Monday, April 13, and a live webcast of the presentation can be accessed here. InMode will also hold virtual one-on-one investor meetings
- INSIDERSEC Form 3 filed by InMode Ltd.3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERSEC Form 3 filed by InMode Ltd.3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mizrahy Moshe3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kreindel Michael3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERSEC Form 3 filed by InMode Ltd.3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERSEC Form 3 filed by InMode Ltd.3 - InMode Ltd. (0001742692) (Issuer)
- INSIDERSEC Form 3 filed by InMode Ltd.3 - InMode Ltd. (0001742692) (Issuer)
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode Announces New Share Repurchase ProgramYOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares. In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash fl
- PRInMode to Present at Upcoming Investor ConferencesYOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 28th Annual Global Healthcare ConferencePresenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetingsLocation: Miami, FLWhen: Wednesday, March 11 at 12:30 pm ETA live webcast of the presentation can be accessed here.Oppenheimer 36th Annual Healthcare MedTech & Services ConferencePresenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial OfficerFormat: Virt
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode Announces Conclusion of Independent Transaction Committee ReviewYOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent transaction committee of its Board of Directors (the "Committee") has completed its review of proposals received in connection with a potential transaction. Since its formation, the Committee has conducted a comprehensive and independent process to evaluate proposals received over the course of its work, with the assistance of external financial and legal advisors.Following a careful review of the final proposals received in connection with the potential transaction, the Committee has concluded
- SECSEC Form S-8 filed by InMode Ltd.S-8 - InMode Ltd. (0001742692) (Filer)
- SECSEC Form 20-F filed by InMode Ltd.20-F - InMode Ltd. (0001742692) (Filer)
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
INMD FAQ
7 questionsWhat does InMode Ltd. do?
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction...Where does INMD stock trade?
InMode Ltd. (INMD) is listed on NASDAQ.What sector and industry is INMD in?
InMode Ltd. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did InMode Ltd. go public?
InMode Ltd. (INMD) completed its IPO in 2019.What are analysts saying about INMD?
InMode Ltd. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-04-29. Recent price targets range from $1600.00 to $4000.00.What companies are similar to INMD?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare INMD side-by-side with any of them on Quantisnow.How can I track INMD on Quantisnow?
Quantisnow aggregates InMode Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INMD to receive live email and push alerts on every new disclosure.